Directing fratricide within T cell products using an anti-uPAR chimeric antigen receptor to drive the production of potent therapeutic cells
The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This fratricide-driven elimination was further confirmed at the T1 time point, where both CAR conditions showed markedly reduced live uPAR+ populations within 24 h of initial mRNA delivery compared to mock controls in which no payload (only water) was delivered by either modality (Figure 7J).”
From Human T cell engineering via serial delivery of mRNA encapsulated within lipid nanoparticles (2026) · cites this paper as [57]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Senolytic CAR T cells reverse senescence-associated pathologies
Amor, C., Feucht, J., Leibold, J., Ho, Y.-J., Zhu, C., Alonso-Curbelo, D., Mansilla-Soto, J., Boyer, J. A., Li, X., Giavridis, T., et al. (2020) · Nature · doi:10.1038/s41586-020-2403-9 · Cited by 1,098
Reprogramming human T cell function and specificity with non-viral genome targeting
Roth, T. L., Puig-Saus, C., Yu, R., Shifrut, E., Carnevale, J., Li, P. J., Hiatt, J., Saco, J., Krystofinski, P., Li, H., et al. (2018) · Nature · doi:10.1038/s41586-018-0326-5 · Cited by 839
Global Manufacturing of CAR T Cell Therapy
Levine, B. L., Miskin, J., Wonnacott, K., & Keir, C. (2017) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2016.12.006 · Cited by 765
The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on/off switch for CAR T cells
Mestermann, K., Giavridis, T., Weber, J., Rydzek, J., Frenz, S., Nerreter, T., Mades, A., Sadelain, M., Einsele, H., & Hudecek, M. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aau5907 · Cited by 531
HLA engineering of human pluripotent stem cells
Riolobos, L., Hirata, R. K., Turtle, C. J., Wang, P.-R., Gornalusse, G. G., Zavajlevski, M., Riddell, S. R., & Russell, D. W. (2013) · Molecular Therapy · doi:10.1038/mt.2013.59 · Cited by 253
CAR-T cell performance: How to improve their persistence?
López-Cantillo, G., Urueña, C., Camacho, B. A., & Ramírez-Segura, C. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.878209 · Cited by 207
Effect of cryopreservation on autologous chimeric antigen receptor T cell characteristics
Panch, S. R., Srivastava, S. K., Elavia, N., McManus, A., Liu, S., Jin, P., Highfill, S. L., Li, X., Dagur, P., Kochenderfer, J. N., et al. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.05.015 · Cited by 107
High-efficiency nonviral CRISPR/Cas9-mediated gene editing of human T cells using plasmid donor DNA
Oh, S. A., Senger, K., Madireddi, S., Akhmetzyanova, I., Ishizuka, I. E., Tarighat, S., Lo, J. H., Shaw, D., Haley, B., & Rutz, S. (2022) · Journal of Experimental Medicine · doi:10.1084/jem.20211530 · Cited by 88
Genome engineering of induced pluripotent stem cells to manufacture natural killer cell therapies
Shankar, K., Capitini, C. M., & Saha, K. (2020) · Stem Cell Research & Therapy · doi:10.1186/s13287-020-01741-4 · Cited by 85
Self-citation
Research works printed but not linked: 65
- Moradi, 2024, Progress and pitfalls of gene editing technology in CAR-T cell therapy: a state-of-the-art review, Front. Oncol., 14, 10.3389/fonc.2024.1388475 · DOI
- Jing, 2021, Cas9-cleavage sequences in size-reduced plasmids enhance nonviral genome targeting of CARs in primary human T cells, Small Methods, 5, 10.1002/smtd.202100071 · DOI
- Tommasi, 2025, Efficient nonviral integration of large transgenes into human T cells using Cas9-CLIPT, Mol. Ther. Methods Clin. Dev., 33, 10.1016/j.omtm.2025.101437 · DOI
- Juillerat, 2020, Straightforward generation of ultrapure off-the-shelf allogeneic CAR-T cells, Front. Bioeng. Biotechnol., 8, 678, 10.3389/fbioe.2020.00678 · DOI
- Chang, 2025, SEED-Selection enables high-efficiency enrichment of primary T cells edited at multiple loci, Nat. Biotechnol., 43, 2043, 10.1038/s41587-024-02531-6 · DOI
- Paul, 2018, Efficient enrichment of gene-modified primary T cells via CCR5-targeted integration of mutant dihydrofolate reductase, Mol. Ther. Methods Clin. Dev., 9, 347, 10.1016/j.omtm.2018.04.002 · DOI
- Valton, 2015, A multidrug-resistant engineered CAR T cell for allogeneic combination immunotherapy, Mol. Ther., 23, 1507, 10.1038/mt.2015.104 · DOI
- Jonnalagadda, 2013, Engineering human T cells for resistance to methotrexate and mycophenolate mofetil as an in vivo cell selection strategy, PLoS One, 8, 10.1371/journal.pone.0065519 · doi:10.1371/journal.pone.0065519
- Liu, 2024, Targeting metabolism to improve CAR-T cells therapeutic efficacy, Chin. Med. J. (Engl.), 137, 909, 10.1097/CM9.0000000000003046 · DOI
- Wang, 2011, A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells, Blood, 118, 1255, 10.1182/blood-2011-02-337360 · DOI · Paper page
- Bister, 2022, Optimized NGFR-derived hinges for rapid and efficient enrichment and detection of CAR T cells in vitro and in vivo, Mol. Ther. Oncolytics, 26, 120, 10.1016/j.omto.2022.05.012 · DOI
- Philip, 2014, A highly compact epitope-based marker/suicide gene for easier and safer T-cell therapy, Blood, 124, 1277, 10.1182/blood-2014-01-545020 · DOI · Paper page
- Tang, 2023, Arming CAR-T cells with cytokines and more: Innovations in the fourth-generation CAR-T development, Mol. Ther., 31, 3146, 10.1016/j.ymthe.2023.09.021 · DOI · Paper page
- Wang, 2021, Bcl-2 enhances chimeric antigen receptor T cell persistence by reducing activation-induced apoptosis, Cancers (Basel), 13, 197, 10.3390/cancers13020197 · DOI
- Zhang, 2024, Unlocking apoptotic pathways: Overcoming tumor resistance in CAR-T-cell therapy, Cancer Med., 13, 10.1002/cam4.70283 · DOI
- Xia, 2024, Reshaping the tumor immune microenvironment to improve CAR-T cell-based cancer immunotherapy, Mol. Cancer, 23, 175, 10.1186/s12943-024-02079-8 · DOI
- Borot, 2025, Multiplex base editing to protect from CD33 directed drugs for immune and gene therapy, Nat. Commun., 16, 4899, 10.1038/s41467-025-59713-2 · DOI
- Guerrero, 2024, GLUT1 overexpression in CAR-T cells induces metabolic reprogramming and enhances potency, Nat. Commun., 15, 8658, 10.1038/s41467-024-52666-y · DOI
- Kawalekar, 2016, Distinct signaling of coreceptors regulates specific metabolism pathways and impacts memory development in CAR T cells, Immunity, 44, 712, 10.1016/j.immuni.2016.02.023 · DOI · Paper page
- Lontos, 2023, Metabolic reprogramming via an engineered PGC-1α improves human chimeric antigen receptor T-cell therapy against solid tumors, J. Immunother. Cancer, 11, 10.1136/jitc-2022-006522 · DOI
- Vormittag, 2018, A guide to manufacturing CAR T cell therapies, Curr. Opin. Biotechnol., 53, 164, 10.1016/j.copbio.2018.01.025 · DOI · Paper page
- Soerens, 2023, Functional T cells are capable of supernumerary cell division and longevity, Nature, 614, 762, 10.1038/s41586-022-05626-9 · DOI · Paper page
- Vučinić, 2025, Impact of cellular composition and T-cell senescence of mononuclear cell concentrates on the manufacturing process of chimeric antigen receptor (CAR) T-cells, Transfusion, 65, 1650, 10.1111/trf.18354 · DOI
- Amor, 2024, Prophylactic and long-lasting efficacy of senolytic CAR T cells against age-related metabolic dysfunction, Nat. Aging, 4, 336, 10.1038/s43587-023-00560-5 · DOI · Paper page
- Yang, 2023, NKG2D-CAR T cells eliminate senescent cells in aged mice and nonhuman primates, Sci. Transl. Med., 15, 10.1126/scitranslmed.add1951 · DOI · Paper page
- Deng, 2024, Targeting senescent cells with NKG2D-CAR T cells, Cell Death Discov., 10, 217, 10.1038/s41420-024-01976-7 · DOI · Paper page
- Zhang, 2026, A convergent uPAR-positive tumor ecosystem creates broad vulnerability to CAR T cell therapy, Cell, 189, 2898, 10.1016/j.cell.2026.03.002 · DOI
- Sarko, 2023, Harnessing chimeric antigen receptor (CAR)-T cells as a potential treatment for Alzheimer’s disease, CGTI, 9, 1003, 10.18609/cgti.2023.132 · DOI
- Wang, 2019, Basing on uPAR-binding fragment to design chimeric antigen receptors triggers antitumor efficacy against uPAR expressing ovarian cancer cells, Biomed. Pharmacother., 117, 10.1016/j.biopha.2019.109173 · DOI · Paper page
- Santi, 2021, The Urokinase Receptor: A Multifunctional Receptor in Cancer Cell Biology. Therapeutic Implications, Int. J. Mol. Sci., 22, 10.3390/ijms22084111 · DOI
- Blasi, 2002, uPAR: a versatile signalling orchestrator, Nat. Rev. Mol. Cel Biol., 3, 932, 10.1038/nrm977 · DOI · Paper page
- Isakov, 2002, Protein kinase C(theta) in T cell activation, Annu. Rev. Immunol., 20, 761, 10.1146/annurev.immunol.20.100301.064807 · DOI · Paper page
- Nykjaer, 1994, Urokinase receptor. An activation antigen in human T lymphocytes, J. Immunol., 152, 505, 10.4049/jimmunol.152.2.505 · DOI · Paper page
- Mueller, 2022, Production and characterization of virus-free, CRISPR-CAR T cells capable of inducing solid tumor regression, J. Immunother. Cancer, 10, 10.1136/jitc-2021-004446 · DOI
- Cappabianca, 2024, Metabolic priming of GD2 TRAC-CAR T cells during manufacturing promotes memory phenotypes while enhancing persistence, bioRxiv
- Shankar, 2025, Virus-free CRISPR knockin of a chimeric antigen receptor into KLRC1 generates potent GD2-specific natural killer cells, Mol. Ther., 33, 1014, 10.1016/j.ymthe.2025.01.024 · DOI
- Eyquem, 2017, Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection, Nature, 543, 113, 10.1038/nature21405 · DOI · Paper page
- Lazzarotto, 2020, CHANGE-seq reveals genetic and epigenetic effects on CRISPR–Cas9 genome-wide activity, Nat. Biotechnol., 38, 1317, 10.1038/s41587-020-0555-7 · DOI · Paper page
- Bozza, 2021, A nonviral, nonintegrating DNA nanovector platform for the safe, rapid, and persistent manufacture of recombinant T cells, Sci. Adv., 7, 10.1126/sciadv.abf1333 · DOI · Paper page
- An, 2024, Enhancement of the viability of T cells electroporated with DNA via osmotic dampening of the DNA-sensing cGAS-STING pathway, Nat. Biomed. Eng., 8, 149, 10.1038/s41551-023-01073-7 · DOI
- Watanabe, 2023, Feasibility and preclinical efficacy of CD7-unedited CD7 CAR T cells for T cell malignancies, Mol. Ther., 31, 24, 10.1016/j.ymthe.2022.09.003 · DOI
- Weber, 2021, Transient rest restores functionality in exhausted CAR-T cells through epigenetic remodeling, Science, 372, 10.1126/science.aba1786 · DOI · Paper page
- Quax, 1998, Binding of human Urokinase-type plasminogen activator to its receptor, Arterioscler. Thromb. Vasc. Biol., 18, 693, 10.1161/01.ATV.18.5.693 · doi:10.1161/01.atv.18.5.693
- Estreicher, 1989, Characterization of the cellular binding site for the urokinase-type plasminogen activator, J. Biol. Chem., 264, 1180, 10.1016/S0021-9258(19)85069-X · DOI · Paper page
- Kouro, 2022, Exhaustion of CAR T cells: potential causes and solutions, J. Transl. Med., 20, 239, 10.1186/s12967-022-03442-3 · DOI
- Avery, 2018, Tim-3 co-stimulation promotes short-lived effector T cells, restricts memory precursors, and is dispensable for T cell exhaustion, Proc. Natl. Acad. Sci. USA, 115, 2455, 10.1073/pnas.1712107115 · DOI · Paper page
- Ferris, 2014, Too much of a good thing? Tim-3 and TCR signaling in T cell exhaustion, J. Immunol., 193, 1525, 10.4049/jimmunol.1400557 · DOI · Paper page
- Hanley, 2019, Fresh versus frozen: Effects of cryopreservation on CAR T cells, Mol. Ther., 27, 1213, 10.1016/j.ymthe.2019.06.001 · DOI
- Machy, 2023, Biology of GD2 ganglioside: implications for cancer immunotherapy, Front. Pharmacol., 14, 10.3389/fphar.2023.1249929 · DOI
- Nazha, 2020, Disialoganglioside GD2 expression in solid tumors and role as a target for cancer therapy, Front. Oncol., 10, 1000, 10.3389/fonc.2020.01000 · DOI · Paper page
- Pluskota, 2003, Convergence of the adhesive and fibrinolytic systems: recognition of urokinase by integrin alpha Mbeta 2 as well as by the urokinase receptor regulates cell adhesion and migration, Blood, 101, 1582, 10.1182/blood-2002-06-1842 · doi:10.1182/blood-2002-06-1842
- Gómez-Melero, 2025, Tandem CAR-T cell therapy: recent advances and current challenges, Front. Immunol., 16, 10.3389/fimmu.2025.1546172 · DOI
- Weinkove, 2019, Selecting costimulatory domains for chimeric antigen receptors: functional and clinical considerations, Clin. Transl. Immunol., 8, 10.1002/cti2.1049 · DOI · Paper page
- Saura-Esteller, 2022, Gamma delta T-cell based cancer immunotherapy: Past-present-future, Front. Immunol., 13, 10.3389/fimmu.2022.915837 · DOI · Paper page
- Hu, 2023, γδ T cells: origin and fate, subsets, diseases and immunotherapy, Signal. Transduct. Target. Ther., 8, 434, 10.1038/s41392-023-01653-8 · DOI · Paper page
- Rassek, 2025, New player in CAR-T manufacture field: comparison of umbilical cord to peripheral blood strategies, Front. Immunol., 16, 10.3389/fimmu.2025.1561174 · DOI
- Ebrahimiyan, 2022, Novel insights in CAR-NK cells beyond CAR-T cell technology; promising advantages, Int. Immunopharmacol., 106, 10.1016/j.intimp.2022.108587 · DOI
- Chang, 1996, Mice lacking the MHC class II transactivator (CIITA) show tissue-specific impairment of MHC class II expression, Immunity, 4, 167, 10.1016/S1074-7613(00)80681-0 · DOI · Paper page
- Hu, 2024, Hypoimmune islets achieve insulin independence after allogeneic transplantation in a fully immunocompetent non-human primate, Cell Stem Cell, 31, 334, 10.1016/j.stem.2024.02.001 · DOI · Paper page
- Sterner, 2021, CAR-T cell therapy: current limitations and potential strategies, Blood Cancer J., 11, 69, 10.1038/s41408-021-00459-7 · DOI · Paper page
- Shahzadi, 2024, Artificial intelligence for chimeric antigen receptor-based therapies: a comprehensive review of current applications and future perspectives, Ther. Adv. Vaccin. Immunother., 12
- Lebrun, 2025, Accelerating CAR-T manufacturing: Establishing an AI and automation-driven analytical development platform, Cytotherapy, 27, 10.1016/j.jcyt.2025.03.249 · doi:10.1016/j.jcyt.2025.03.249
- Daniels, 2022, Decoding CAR T cell phenotype using combinatorial signaling motif libraries and machine learning, Science, 378, 1194, 10.1126/science.abq0225 · DOI
- Sin, 2024, A high-density microfluidic bioreactor for the automated manufacturing of CAR T cells, Nat. Biomed. Eng., 8, 1571, 10.1038/s41551-024-01219-1 · DOI
- Stringer, 2021, Cellpose: a generalist algorithm for cellular segmentation, Nat. Methods, 18, 100, 10.1038/s41592-020-01018-x · DOI · Paper page
Cited by
Human T cell engineering via serial delivery of mRNA encapsulated within lipid nanoparticles
Ramamurthy, A., Scimonelli, G., Murphy, W. L., & Saha, K. (2026) · Molecular Therapy Nucleic Acids · doi:10.1016/j.omtn.2026.103081
Self-citation
Metadata
- Authors
- Sarko, L. E., Givand, D., Rattin, B., Shepley, C., Tommasi, A., Attar, A., Taylor, R., Kutler, B., Traynor, R. M., Upadhyaya, A., Mnuk, M., Gehrke, C., Murren, N., Ulland, T. K., Capitini, C. M., Kotanchek, T., & Saha, K.
- ORCID
- Saha, Krishanu
- Venue
- Molecular Therapy
- Publisher
- Elsevier BV
- Published
- 2026-09
- Volume
- 34
- Issue
- 9
- Pages
- 5190-5206
- ISSN
- 1525-0016
- Cited by
- 2
- References
- 9
- Language
- en
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (am, 366 d)
- Funders
- National Science Foundation
- National Cancer Institute (R01 CA278051)
- National Institutes of Health
- Wisconsin Alumni Research Foundation Inc
- Midwest Athletes Against Childhood Cancer
- Saint Baldricks Foundation
- University of Wisconsin-Madison
- Grainger Institute for Engineering, University of Wisconsin-Madison
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Directing fratricide within T cell products using an anti-uPAR chimeric antigen receptor to drive the production of potent therapeutic cells. https://app.cochat.ai/papers/10.1016/j.ymthe.2026.05.029
- The paper
- Sarko, L. E., Givand, D., Rattin, B., Shepley, C., Tommasi, A., Attar, A., Taylor, R., Kutler, B., Traynor, R. M., Upadhyaya, A., Mnuk, M., Gehrke, C., Murren, N., Ulland, T. K., Capitini, C. M., Kotanchek, T., & Saha, K. (2026). Directing fratricide within T cell products using an anti-uPAR chimeric antigen receptor to drive the production of potent therapeutic cells. Molecular Therapy. https://doi.org/10.1016/j.ymthe.2026.05.029
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.